Compare Ionis Pharmaceuticals Inc. Common Stock (IONS) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ionis Pharmaceuticals Inc. Common Stock vs KLA Corp. — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $44.17 (market cap $7.10B), while KLA Corp. trades at $172.58 (market cap $233.35B). The key difference: KLA Corp. is far larger — about 32.9× Ionis Pharmaceuticals Inc. Common Stock's market cap, and KLA Corp. pays a 0.51% dividend while Ionis Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and KLA Corp. for 60 Days on average.
| IONS | KLAC | |
|---|---|---|
Market Cap | $7.10B | $233.35B |
Volume | 2,027,457 | 14,457,699 |
Sector | Health | Technology |
52-Week High | $86.50 | $301.71 |
52-Week Low | $42.38 | $108.70 |
Typical Hold Time | 0 Days | 60 Days |
Enterprise Value | $6.66B | $234.60B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
KLA Corporation (KLAC) trades at $184.00, down 3.22% on the day, with strong technical support at $185. The stock shows robust fundamentals with Q2 2026 EPS beating expectations at $1.05 versus $1.00 estimate, continuing a pattern of earnings outperformance. Revenue reached $12.16B in 2025 with impressive 35.57% net income margin and 87.5% ROE, though valuation multiples remain elevated with P/E at 48.86. Recent news highlights AI-driven demand growth and a $12.57B backlog supporting revenue visibility.
Outlook remains positive with analyst consensus price target of $223.88 suggesting 22% upside potential. Investment opportunity centers on AI infrastructure growth and advanced packaging demand, though risks include competitive pressures from AMAT and ASML, high valuation multiples, and potential margin compression. The company's capital return program targeting over 90% of free cash flow provides shareholder support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ionis Pharmaceuticals Inc. Common Stock
Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
